Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are an important class of therapeutics, incorporate a heterocyclic core in their molecular structure and are used for the alleviation of pain and inflammation associated with several pathological conditions. NSAIDs exert anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COXs) which, are useful in the synthesis of prostanoids generated from arachidonic acid. Selective COX-II inhibitors, compared to nonselective inhibitors exhibit reduced gastrointestinal, ulceration and renal side effects. In general, COX-II inhibitors incorporate a five or six-membered heterocyclic motif with built-in sulfonamide or methylsulfonate moiety. Celecoxib, a selective COX-II inhibitor drug, commercialized by Pfizer is applied in the treatment of rheumatoid arthritis, osteoarthritis, and painful menstruation related symptoms. The current review provides a discussion on the methodologies used to construct celecoxib/celebrex® and structural analogs.
Keywords: Celecoxib, Celebrex®, Pyrazoles, Heterocycles, COX, Cycloadditions, Couplings, and Condensations
Current Organic Chemistry
Title:Synthesis of Celecoxib and Structural Analogs- A Review
Volume: 16 Issue: 11
Author(s): Sureshbabu Dadiboyena and Ashton T. Hamme II
Affiliation:
Keywords: Celecoxib, Celebrex®, Pyrazoles, Heterocycles, COX, Cycloadditions, Couplings, and Condensations
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are an important class of therapeutics, incorporate a heterocyclic core in their molecular structure and are used for the alleviation of pain and inflammation associated with several pathological conditions. NSAIDs exert anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COXs) which, are useful in the synthesis of prostanoids generated from arachidonic acid. Selective COX-II inhibitors, compared to nonselective inhibitors exhibit reduced gastrointestinal, ulceration and renal side effects. In general, COX-II inhibitors incorporate a five or six-membered heterocyclic motif with built-in sulfonamide or methylsulfonate moiety. Celecoxib, a selective COX-II inhibitor drug, commercialized by Pfizer is applied in the treatment of rheumatoid arthritis, osteoarthritis, and painful menstruation related symptoms. The current review provides a discussion on the methodologies used to construct celecoxib/celebrex® and structural analogs.
Export Options
About this article
Cite this article as:
Dadiboyena Sureshbabu and T. Hamme II Ashton, Synthesis of Celecoxib and Structural Analogs- A Review, Current Organic Chemistry 2012; 16 (11) . https://dx.doi.org/10.2174/138527212800672664
DOI https://dx.doi.org/10.2174/138527212800672664 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances and Challenges in the Synthesis of Highly Oxidised Natural Phenols with Antiviral, Antioxidant and Cytotoxic Activities
Current Medicinal Chemistry Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Cardiac SPECT-CT and PET-CT Imaging
Current Medical Imaging The CLCA Gene Family A Novel Family of Putative Chloride Channels
Current Genomics The Application of Modified SBA-15 as a Chemosensor
Current Nanomaterials Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry A Review of Ensemble Methods in Bioinformatics
Current Bioinformatics Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design High-Throughput Structural Biology in Drug Discovery: Protein Kinases
Current Pharmaceutical Design Adeno-Associated Virus Vectors: Immunobiology and Potential Use for Immune Modulation
Current Gene Therapy Synthesis, Biological Evaluation and Molecular Docking Studies of Pyridine Incorporated Chalcone Derivatives as Anticancer Agents
Letters in Organic Chemistry Molecular Markers of Cardiovascular Damage in Hypertension
Current Pharmaceutical Design TGF-β: Its Role in Asthma and Therapeutic Potential
Current Drug Targets Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design New Frontiers in Cystic Fibrosis Therapy: The Case of Stem Cells
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets